Aelin Therapeutics

Aelin Therapeutics, founded in 2017 as a spin-off from VIB and partner universities KU Leuven, VUB, and UGent, is a privately held Belgian company. The company has secured a 27 million Euro Series A investment from a reputable investor syndicate. Aelin Therapeutics specializes in developing Pept-ins™ technology, a novel class of peptide-based therapeutics designed to target high-value undruggable proteins. These proteins are often involved in diseases such as cancer, where traditional drug modalities have failed. The company leverages its unique mode of action, designability, and intracellular target space to create effective treatments. Pept-ins™ can be tailored to target either a single protein or an entire family of proteins, offering broad applicability. Proofs of concept have demonstrated the technology's potential in functional knockdown of mammalian, bacterial, viral, and fungal protein targets for the treatment of human diseases. Aelin Therapeutics operates in the biotechnology and pharmaceutical markets, primarily serving clients in the healthcare sector. The business model focuses on research and development, with revenue generated through partnerships, licensing agreements, and potential future product sales.

Keywords: Pept-ins™, undruggable proteins, oncology, peptide-based therapeutics, biotechnology, pharmaceutical, rational design, intracellular targets, Series A investment, VIB spin-off.